Results 51 to 60 of about 4,126 (156)

The adjuvant system AS01 up-regulates neutrophil CD14 expression and neutrophil-associated antigen transport in the local lymphatic network

, 2018
Summary The liposome-based adjuvant system AS01 is under evaluation for use in several vaccines in clinical development. We have shown previously that AS01 injected with hepatitis B surface antigen (HBsAg) induces a distinct cellular ...
E N T Meeusen, Neeland, M R, M R Neeland, W Shi, de Veer, M J, Shi, W, Meeusen, E N T, A M Didierlaurent, M J de Veer, Didierlaurent, Arnaud, C Collignon, Collignon, C   +11 more
core   +1 more source

Reactogenicity and Immunogenicity of RSV Vaccines in Immunocompromised Individuals With Hematological Malignancies

Transplant Infectious Disease, EarlyView.
In adults with hematologic malignancies, RSV vaccination was safe and induced antibody and T‐cell responses. However, antibody levels were lower and declined more rapidly than in healthy controls. While early immune responses were evident, reduced magnitude and durability of protection suggest the need for optimized vaccination strategies in this high ...
Alisse Hannaford, Zoe Swank, Simon D. van Haren, Natalie Izaguirre, Caitlin Syphurs, Zhou Lan, Bridget Yates, Urwah Kanwal, Grace Valentine, Ella Woehl, David Regan, Hannah Levine, Alexandra Tong, Maria Shehata, Fathia Oladipupo, Colleen Sedney, Kevin Ryff, Sanya Thomas, Joann Diray‐Arce, Xiaofang Li, Kimberly A. Dufresne, Lindsey A. Parisi, Aidan Eustace, Louise Hansen, David R. Walt, Ofer Levy, Amar Kelkar, Robert J. Soiffer, Vincent T. Ho, Lindsey R. Baden, Nicolas C. Issa, Ann E. Woolley, Amy C. Sherman   +32 more
wiley   +1 more source

Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria

Medicinal Research Reviews, Volume 46, Issue 6, Page 1477-1498, November 2026.
ABSTRACT Malaria is a global health threat, with an estimated 282 million cases and 610,000 malaria‐associated deaths reported in 2024. Most mortality is due to infection by Plasmodium falciparum parasites, with the highest burden occurring in Sub‐Saharan Africa.
Wisam A. Dawood, Jacinta R. Macdonald, Christian Anzenhofer, Tina S. Skinner‐Adams, Robert C. Reid, Thomas Kurz, David P. Fairlie, Katherine T. Andrews   +7 more
wiley   +1 more source

The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease [PDF]

, 2015
Recent publications have reported follow-up of the RTS,S/AS01 malaria vaccine candidate Phase III trials at 11 African sites for 32 months (or longer).
Peter Pemberton-Ross, Melissa A. Penny, Smith, Thomas A., Thomas A. Smith, Pemberton-Ross, Peter, Penny, Melissa A., Smith TA, Pemberton-Ross P, Penny MA   +8 more
core   +1 more source

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. [PDF]

, 2012
\ud \ud The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial.
Abdulla, Salim, Sillman, Marla, Maingi, Charity, Aide, Pedro, Kremsner, Peter Gottfried, Adjei, George, Otsyula, Nekoye, Abdul, Omari, Leach, Amanda, Methogo, Barbara Gaelle Nfono Ondo, Bejon, Philip, Gondi, Stacey, Aponte, John J, Guerra, Yolanda, Chandramohan, Daniel, Malle, Lincoln, Liheluka, Edwin, Kilembe, Jane, Loucq, Christian, Odongo, George, Jongert, Erik, Otieno, Walter, Mordmüller, Benjamin, Slutsker, Laurence, Agyekum, Alex, Ofori-Anyinam, Opokua, Hamad, Ali Said, Tsidya, Mercy, Vansadia, Preeti, Sigauque, Betuel, Lanaspa, Miguel, Tegha, Gerald, Drakeley, Chris, Kwara, Evans, Kabwende, Anita Lumeka, Asante, Isaac, Gesase, Samwel, Cohen, Joe, Ogutu, Bernhards, Agnandji, Selidji Todagbe, Otieno, Lucas, Sambian, David, Ansong, Daniel, Lell, Bertrand, Awino, Norbert, McMorrow, Meredith, Carter, Terrell, Hoffman, Irving, Schellenberg, David, Radford, Afiya, Minja, Rose, Mwambingu, Gabriel, Kaslow, David, Kerubo, Christine, Tembo, Tapiwa, Mutani, Paul, Ahmed, Saumu, Odero, Chris, Vekemans, Johan, Muturi-Kioi, Vincent, Mvalo, Tisungane, RTS,S Clinical Trials Partnership, Dosoo, David, Ouédraogo, Jean Bosco, Rettig, Theresa, Sarfo, Anima, Sorgho, Hermann, Osei-Kwakye, Kingsley, Agbenyega, Tsiri, Olivier, Aurélie, Owira, Victorine, Issifou, Saadou, Kaboré, Berenger, Kariuki, Simon, Oneko, Martina, Otieno, Kephas, Olotu, Ally, Lapierre, Didier, Fernandes, José Francisco, Ali, Ali Mohammed, Oguk, Esther, Boahen, Owusu, Sylverken, Justice, Hamel, Mary J, Machevo, Sonia, Macete, Eusébio, Asante, Kwaku Poku, Owusu-Agyei, Seth, Lemnge, Martha, Alonso, Pedro, Theander, Thor G, Kamthunzi, Portia, Otieno, Allan, Nkomo, Rutendo, Ballou, W Ripley, Lievens, Marc, Abossolo, Béatrice Peggy, Bulo, Helder, Marsh, Kevin, Woods, Jon Ben, Mahende, Coline, Bawa, John, Akoo, Pauline, Adjei, Samuel, Njuguna, Patricia, Leboulleux, Didier, Sombié, Olivier, Greenwood, Brian, Malabeja, Anangisye, Chilengi, Roma, D'Alessandro, U., Guiguemdé, Robert Tinga, Tinto, Halidou, Guiraud, Issa, Martinson, Francis, Lusingu, John, Boateng, Harry Owusu, Mpina, Maxmillian, Lang, Trudie, Sacarlal, Jahit, Chawinga, Chimwemwe, The RTS, S. Clinical Trials Partnership, Mtoro, Ali Takadir, Tanner, Marcel, Laserson, Kayla F, Savarese, Barbara, Valea, Innocent, D'Alessandro, Umberto, Salim, Nahya, Adegnika, Ayola Akim, Acacio, Sozinho, Bihoun, Biébo, D’Alessandro, Umberto, Aponte, John J., Laserson, Kayla F., Ben Woods, Jon, Poku Asante, Kwaku, Theander, Thor G., Ballou, W. Ripley, Hamel, Mary J.   +139 more
core   +2 more sources

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. [PDF]

, 2013
BACKGROUND: The efficacy of RTS,S/AS01 as a vaccine for malaria is being tested in a phase 3 clinical trial. Early results show significant, albeit partial, protection against clinical malaria and severe malaria.
Abdulla, Salim, Ghani, Azra C, Asante, Kwaku Poku, White, Michael T, Owusu-Agyei, Seth, Lusingu, John PA, Bejon, Philip, Agnandji, Selidji T, Otsyula, Nekoye N, Olotu, Ally, Bojang, Kalifa, Salim, Nahya   +11 more
core   +1 more source

Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques. [PDF]

PLoS ONE, 2015
HIV-1-specific CD4+ and CD8+ T lymphocytes are important for HIV-1 replication control. F4/AS01 consists of F4 recombinant fusion protein (containing clade B Gag/p24, Pol/RT, Nef and Gag/p17) formulated in AS01 Adjuvant System, and was shown to induce F4-
Clarisse Lorin, Yannick Vanloubbeeck, Sébastien Baudart, Michaël Ska, Babak Bayat, Geoffroy Brauers, Géraldine Clarinval, Marie-Noëlle Donner, Martine Marchand, Marguerite Koutsoukos, Pascal Mettens, Joe Cohen, Gerald Voss   +12 more
doaj   +1 more source

Knowledge, Perception, and Intention to Promote Malaria Vaccination Among Students in Southwestern Nigeria: A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Introduction Malaria remains a major public health burden in Nigeria, and the introduction of malaria vaccines offers a promising strategy for reducing morbidity and mortality. This study assessed knowledge, perception, and intention to promote malaria vaccination among health technology students in Southwestern Nigeria.
James Success Odubia, Majani Edward
wiley   +1 more source

Impact of high human genetic diversity in Africa on immunogenicity and efficacy of RTS,S/AS01 vaccine [PDF]

, 2023
In modern medicine, vaccination is one of the most effective public health strategies to prevent infectious diseases. Indisputably, vaccines have saved millions of lives by reducing the burden of many serious infections such as polio, tuberculosis ...
Ssewanyana, Isaac, Nankabirwa, Sserwadda, Ivan, Kamya, Moses R., Gerald Mboowa, Arinaitwe, Emmanuel, Jagannathan, Prasanna, Emmanuel Arinaitwe, Prasanna Jagannathan, Taremwa, Yoweri, Ivan Sserwadda, Gerald Tumusiime, Annettee Nakimuli, Nankabirwa, Joaniter I., Stephen Tukwasibwe, Nakimuli, Annettee, Isaac Ssewanyana, Tumusiime, Gerald, Tukwasibwe, Stephen, Joaniter, Joaniter I. Nankabirwa, Moses R. Kamya, Yoweri Taremwa, Mboowa, Gerald   +23 more
core   +1 more source

Community‐Centric Malaria Prevention in Sub‐Saharan Africa: A Narrative Review of Pathways to Elimination and Global Health Impact

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aims Malaria remains a major global health challenge, with the World Health Organization (WHO) African Region accounting for the overwhelming majority of malaria cases and deaths worldwide. This narrative review examines the contribution of community‐centric malaria prevention approaches to malaria elimination pathways and their
Emmanuel Ifeanyi Obeagu
wiley   +1 more source